Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 241 participants.

Also called NCT01534962

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 241 participants (enrolled count) (from the registry)
Sponsor
Menarini Group (from the registry)
Registry
  • NCT NCT01534962
  • EudraCT 2011-002789-18
Other papers using this trial's data
  • Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study Heart rhythm, 2015-05 DOI, PubMed 25602175

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Germany, Italy, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01534962. Randomized; quadruple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-10 (actual). Results posted on 2014-08-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
Acronym
RAFFAELLO
Condition
Persistent Atrial Fibrillation
Intervention (Drug)
Ranolazine
Intervention (Drug)
Ranolazine
Intervention (Drug)
Ranolazine
Intervention (Drug)
Placebo
Lead sponsor
Menarini Group (class: industry)

Record details

Record id
cardio:ct-nct01534962
Content hash
ee4ffb95b16bb87fd355d5350bab5907fcd4b97851299b08f4805a6900363eb2